NCT06337084 - Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 30, 2024

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions

Solid Tumor, AdultBladder CancerUrothelial CarcinomaTriple-negative Breast CancerLung CancerColorectal CancerGastric CancerOvarian CancerPancreatic Cancer

Interventions

DRUG

MNPR-101-DFO*-89Zr

Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans

DIAGNOSTIC_TEST

PET/CT Diagnostic Imaging

PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.

Trial Locations (1)

3051

RECRUITING

Melbourne Theranostic Innovation Centre (MTIC), North Melbourne